Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases

Fasting and postprandial hypertriglyceridemia is a risk factor for atherosclerotic cardiovascular diseases (ASCVD). Fibrates have been used to treat dyslipidemia, particularly hypertriglyceridemia, and low HDL-cholesterol (HDL-C). However, conventional fibrates have low selectivity for peroxisome pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Shizuya, Masuda, Daisaku, Matsuzawa, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514171/
https://www.ncbi.nlm.nih.gov/pubmed/30930344
http://dx.doi.org/10.5551/jat.48918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514171/
https://www.ncbi.nlm.nih.gov/pubmed/30930344
http://dx.doi.org/10.5551/jat.48918

Ejemplares similares